253 related articles for article (PubMed ID: 34719645)
1. Temozolomide Induces Endocytosis of EGFRvIII via p38-Mediated Non-canonical Phosphorylation in Glioblastoma Cells.
Haryuni RD; Tanaka T; Takahashi JI; Onuma I; Zhou Y; Yokoyama S; Sakurai H
Biol Pharm Bull; 2021; 44(11):1681-1687. PubMed ID: 34719645
[TBL] [Abstract][Full Text] [Related]
2. EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma.
Li L; Puliyappadamba VT; Chakraborty S; Rehman A; Vemireddy V; Saha D; Souza RF; Hatanpaa KJ; Koduru P; Burma S; Boothman DA; Habib AA
Oncogene; 2015 Jan; 34(1):129-134. PubMed ID: 24362532
[TBL] [Abstract][Full Text] [Related]
3. Epigenomic perturbation of novel EGFR enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide.
Vincent CA; Nissen I; Dakhel S; Hörnblad A; Remeseiro S
BMC Cancer; 2023 Oct; 23(1):945. PubMed ID: 37803333
[TBL] [Abstract][Full Text] [Related]
4. WASH and Tsg101/ALIX-dependent diversion of stress-internalized EGFR from the canonical endocytic pathway.
Tomas A; Vaughan SO; Burgoyne T; Sorkin A; Hartley JA; Hochhauser D; Futter CE
Nat Commun; 2015 Jun; 6():7324. PubMed ID: 26066081
[TBL] [Abstract][Full Text] [Related]
5. Genome-Wide CRISPR-Cas9 Screening Identifies NF-κB/E2F6 Responsible for EGFRvIII-Associated Temozolomide Resistance in Glioblastoma.
Huang K; Liu X; Li Y; Wang Q; Zhou J; Wang Y; Dong F; Yang C; Sun Z; Fang C; Liu C; Tan Y; Wu X; Jiang T; Kang C
Adv Sci (Weinh); 2019 Sep; 6(17):1900782. PubMed ID: 31508283
[TBL] [Abstract][Full Text] [Related]
6. Stress-specific p38 MAPK activation is sufficient to drive EGFR endocytosis but not its nuclear translocation.
Tomas A; Jones S; Vaughan SO; Hochhauser D; Futter CE
J Cell Sci; 2017 Aug; 130(15):2481-2490. PubMed ID: 28646091
[TBL] [Abstract][Full Text] [Related]
7. Ribozyme-mediated inhibition of 801-bp deletion-mutant epidermal growth factor receptor mRNA expression in glioblastoma multiforme.
Karpel-Massler G; Wirtz CR; Halatsch ME
Molecules; 2010 Jun; 15(7):4670-8. PubMed ID: 20657384
[TBL] [Abstract][Full Text] [Related]
8. EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266-283 antitumor response in preclinical glioblastoma models.
Álvarez-Vázquez A; San-Segundo L; Cerveró-García P; Flores-Hernández R; Ollauri-Ibáñez C; Segura-Collar B; Hubert CG; Morrison G; Pollard SM; Lathia JD; Sánchez-Gómez P; Tabernero A
Neuro Oncol; 2024 Mar; ():. PubMed ID: 38507464
[TBL] [Abstract][Full Text] [Related]
9. Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug.
Bi J; Khan A; Tang J; Armando AM; Wu S; Zhang W; Gimple RC; Reed A; Jing H; Koga T; Wong IT; Gu Y; Miki S; Yang H; Prager B; Curtis EJ; Wainwright DA; Furnari FB; Rich JN; Cloughesy TF; Kornblum HI; Quehenberger O; Rzhetsky A; Cravatt BF; Mischel PS
Cell Rep; 2021 Nov; 37(5):109957. PubMed ID: 34731610
[TBL] [Abstract][Full Text] [Related]
10. Chlorpromazine induces cytotoxic autophagy in glioblastoma cells via endoplasmic reticulum stress and unfolded protein response.
Matteoni S; Matarrese P; Ascione B; Ricci-Vitiani L; Pallini R; Villani V; Pace A; Paggi MG; Abbruzzese C
J Exp Clin Cancer Res; 2021 Nov; 40(1):347. PubMed ID: 34740374
[TBL] [Abstract][Full Text] [Related]
11. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
[No Abstract] [Full Text] [Related]
12. Effect of long-term adjuvant temozolomide chemotherapy on primary glioblastoma patient survival.
Huang B; Yu Z; Liang R
BMC Neurol; 2021 Nov; 21(1):424. PubMed ID: 34724914
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide abrogates the aggressiveness of urothelial carcinoma cells by enhancing senescence and depleting the side population.
Kim NY; Hwang SH; Yang Y; Kim Y
Oncol Lett; 2021 Dec; 22(6):845. PubMed ID: 34733363
[TBL] [Abstract][Full Text] [Related]
14. Rh-endostatin combined with chemotherapy in patients with advanced or recurrent mucosal melanoma: retrospective analysis of real-world data.
Zhang X; Jin F; Jiang S; Cao J; Meng Y; Xu Y; ChunmengWang ; Chen Y; Yang H; Kong Y; Liu X; Luo Z
Invest New Drugs; 2022 Apr; 40(2):453-460. PubMed ID: 34731354
[TBL] [Abstract][Full Text] [Related]
15. Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With
Tada H; Mitsudomi T; Misumi T; Sugio K; Tsuboi M; Okamoto I; Iwamoto Y; Sakakura N; Sugawara S; Atagi S; Takahashi T; Hayashi H; Okada M; Inokawa H; Yoshioka H; Takahashi K; Higashiyama M; Yoshino I; Nakagawa K;
J Clin Oncol; 2022 Jan; 40(3):231-241. PubMed ID: 34726958
[TBL] [Abstract][Full Text] [Related]
16. Olaparib Is a Mitochondrial Complex I Inhibitor That Kills Temozolomide-Resistant Human Glioblastoma Cells.
Zampieri LX; Sboarina M; Cacace A; Grasso D; Thabault L; Hamelin L; Vazeille T; Dumon E; Rossignol R; Frédérick R; Sonveaux E; Lefranc F; Sonveaux P
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769368
[TBL] [Abstract][Full Text] [Related]
17. Delivery of gefitinib in synergism with thymoquinone
Upadhyay P; Ghosh A; Basu A; Pranati PA; Gupta P; Das S; Sarker S; Bhattacharjee M; Bhattacharya S; Ghosh S; Chattopadhyay S; Adhikary A
Biomater Sci; 2021 Dec; 9(24):8285-8312. PubMed ID: 34766965
[TBL] [Abstract][Full Text] [Related]
18. Sustained reduction of discharge opioid prescriptions in an enhanced recovery after thoracic surgery program: A multilevel generalized linear model.
Zorrilla-Vaca A; Rice D; Brown JK; Antonoff M; Sepesi B; Hofstetter W; Swisher S; Walsh G; Vaporciyan A; Mehran R; Hagberg C; Mena GE
Surgery; 2022 Feb; 171(2):504-510. PubMed ID: 34740455
[TBL] [Abstract][Full Text] [Related]
19. The relationship between the degree of brain edema regression and changes in cognitive function in patients with recurrent glioma treated with bevacizumab and temozolomide.
Wang X; Chen D; Qiu J; Li S; Zheng X
Quant Imaging Med Surg; 2021 Nov; 11(11):4556-4568. PubMed ID: 34737923
[TBL] [Abstract][Full Text] [Related]
20. Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma.
Yumioka T; Honda M; Shimizu R; Teraoka S; Yamaguchi N; Kawamoto B; Iwamoto H; Morizane S; Hikita K; Takenaka A
Anticancer Res; 2021 Nov; 41(11):5767-5773. PubMed ID: 34732450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
